Research
Hormonal
If metformin is contraindicated or not tolerated, other oral hypoglycemic agents (DPP4 inhibitors, SGLT2 inhibitors, Sulfonylureas, etc.) can be used as initial monotherapy based on clinical situation.
If you can't take metformin, your doctor will choose another medication based on your specific health needs, such as kidney function or heart risk. Options include DPP4 inhibitors, SGLT2 inhibitors, or others.
GoodConditionalHIGH confidence
If metformin is contraindicated or not well tolerated as the initial treatment, another class of hypoglycemic agent can be used depending on the clinical situation
Why this rating
Based on systematic review of guidelines and clinical trials.
Source
Monotherapy in patients with type 2 diabetes mellitus
Sang Youl Rhee et al. · The Korean Journal of Internal Medicine · 2017
DOI 10.3904/kjim.2017.312
clinical_guidelineCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →